Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
12
10
2019
pubmed:
15
5
2020
medline:
2
4
2021
entrez:
15
5
2020
Statut:
ppublish
Résumé
The degree of metabolic activity in tumor cells can be determined by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET). Associations between FDG uptake by primary tumors of locally advanced esophageal squamous cell carcinoma (ESCC) under trimodal therapy and the pathological features of such tumors have not been fully investigated. We evaluated relationships between the maximal standardized uptake (SUVmax) in primary tumors on preoperative PET images and pathological features as well as cancer recurrence in 143 patients with ESCC who underwent neoadjuvant chemoradiotherapy (NCRT) followed by surgery. The post-SUVmax significantly differed after NCRT for ypT and ypN status, lymphatic invasion (LI), venous invasion (VI), and recurrence. Furthermore, the %ΔSUVmax (rate of decrease between before and after NCRT) for LI, VI, and recurrence significantly differed. Univariate and multivariate analyses selected post-SUVmax and %ΔSUVmax as independent preoperative predictors of recurrence-free survival [hazard ratio (HR) 1.46; 95% confidence interval (CI) 1.24-1.72 and HR 0.97; 95% CI 0.96-0.99, respectively; p < 0.001 for both]. Recurrence-free and overall survival were significantly stratified according to optimal SUVmax cutoffs for predicting recurrence (post- and %ΔSUVmax: 2.8 and 70, respectively). The post- and %ΔSUVmax of primary tumors were significantly associated with the pathological features and recurrence of ESCC under trimodal therapy. Therefore, FDG-PET can preoperatively predict the degree of aggressive tumor behavior in ESCC under trimodal therapy.
Sections du résumé
BACKGROUND
BACKGROUND
The degree of metabolic activity in tumor cells can be determined by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET). Associations between FDG uptake by primary tumors of locally advanced esophageal squamous cell carcinoma (ESCC) under trimodal therapy and the pathological features of such tumors have not been fully investigated.
PATIENTS AND METHODS
METHODS
We evaluated relationships between the maximal standardized uptake (SUVmax) in primary tumors on preoperative PET images and pathological features as well as cancer recurrence in 143 patients with ESCC who underwent neoadjuvant chemoradiotherapy (NCRT) followed by surgery.
RESULTS
RESULTS
The post-SUVmax significantly differed after NCRT for ypT and ypN status, lymphatic invasion (LI), venous invasion (VI), and recurrence. Furthermore, the %ΔSUVmax (rate of decrease between before and after NCRT) for LI, VI, and recurrence significantly differed. Univariate and multivariate analyses selected post-SUVmax and %ΔSUVmax as independent preoperative predictors of recurrence-free survival [hazard ratio (HR) 1.46; 95% confidence interval (CI) 1.24-1.72 and HR 0.97; 95% CI 0.96-0.99, respectively; p < 0.001 for both]. Recurrence-free and overall survival were significantly stratified according to optimal SUVmax cutoffs for predicting recurrence (post- and %ΔSUVmax: 2.8 and 70, respectively).
CONCLUSIONS
CONCLUSIONS
The post- and %ΔSUVmax of primary tumors were significantly associated with the pathological features and recurrence of ESCC under trimodal therapy. Therefore, FDG-PET can preoperatively predict the degree of aggressive tumor behavior in ESCC under trimodal therapy.
Identifiants
pubmed: 32405978
doi: 10.1245/s10434-020-08609-0
pii: 10.1245/s10434-020-08609-0
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4422-4430Références
Sjoquist KM, Burmeister BH, Smithers BM, et al; Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12: 681–692.
Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017; 390: 2383–96.
pubmed: 28648400
doi: 10.1016/S0140-6736(17)31462-9
van Hagen P, Hulshof MC, van Lanschot JJ, et al. CROSS Group: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074–84.
pubmed: 22646630
doi: 10.1056/NEJMoa1112088
Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodal therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26: 1086–92.
pubmed: 18309943
pmcid: 5126644
doi: 10.1200/JCO.2007.12.9593
Sepesi B, Schmidt HE, Lada M, et al. Survival in patients with esophageal adenocarcinoma undergoing trimodality therapy is independent of regional lymph node location. Ann Thorac Surg. 2016; 101:1075–80.
pubmed: 26680311
doi: 10.1016/j.athoracsur.2015.09.063
Akutsu Y, Shuto K, Kono T, et al. The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. J Surg Oncol. 2012; 105: 756–60.
pubmed: 22162007
doi: 10.1002/jso.23007
Hamai Y, Hihara J, Emi M, et al. Evaluation of prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy followed by surgery. World J Surg. 2018; 42: 1496–1505.
pubmed: 29030675
doi: 10.1007/s00268-017-4283-1
Hamai Y, Emi M, Ibuki Y, et al. Early recurrence and cancer death after trimodal therapy for esophageal squamous cell carcinoma. Anticancer Res. 2019; 39: 1433–1440.
pubmed: 30842179
doi: 10.21873/anticanres.13259
Chen WH, Huang YL, Chao YK, et al. Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2015; 22: 338–43.
pubmed: 25023545
doi: 10.1245/s10434-014-3881-5
Hamai Y, Hihara J, Taomoto J, Yamakita I, Ibuki Y, Okada M. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer. Dis Esophagus. 2015; 28: 358–64.
pubmed: 24612033
doi: 10.1111/dote.12207
Schmidt T, Lordick F, Herrmann K, Ott K. Value of functional imaging by PET in esophageal cancer. J Natl Compr Canc Netw. 2015; 13: 239–47.
pubmed: 25691614
doi: 10.6004/jnccn.2015.0030
Hamai Y, Hihara J, Emi M, et al. Ability of fluorine-18 fluorodeoxyglucose positron emission tomography to predict outcomes of neoadjuvant chemoradiotherapy followed by surgical treatment for esophageal squamous cell carcinoma. Ann Thorac Surg. 2016; 102: 1132–39.
pubmed: 27319990
doi: 10.1016/j.athoracsur.2016.04.011
Cong L, Wang S, Gao T, Hu L. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis. Jpn J Clin Oncol. 2016; 46:1118–26.
pubmed: 27702836
Sobin L, Gospodarowicz M, Wittekind C, eds. International Union Against Cancer (UICC): TNM classification of malignant tumours (7th edition). Wiley: New York, 2009.
Hamai Y, Hihara J, Emi M, et al. Results of neoadjuvant chemoradiotherapy with docetaxel and 5-fluorouracil followed by esophagectomy to treat locally advanced esophageal cancer. Ann Thorac Surg. 2015; 99: 1887–93.
pubmed: 25912745
doi: 10.1016/j.athoracsur.2015.02.042
Emi M, Hihara J, Hamai Y, et al. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. Cancer Chemother Pharmacol. 2012; 69: 1499–505.
pubmed: 22382882
doi: 10.1007/s00280-012-1853-7
Hamai Y, Hihara J, Emi M, et al. Effects of neoadjuvant chemoradiotherapy on pathological TNM Stage and their prognostic significance for surgically-treated esophageal squamous cell carcinoma. Anticancer Res. 2017; 37: 5639–46.
pubmed: 28982881
Murakami Y, Hamai Y, Emi M, et al. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma. J Radiat Res. 2018; 59: 616–24.
pubmed: 29939306
pmcid: 6151632
doi: 10.1093/jrr/rry047
Lee JR, Madsen MT, Bushnel D, Menda Y. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun. 2000; 21: 685–90.
pubmed: 10994673
doi: 10.1097/00006231-200007000-00013
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205–16.
pubmed: 10655437
doi: 10.1093/jnci/92.3.205
Beseth BD, Bedford R, Isacoff WH, Holmes EC, Cameron RB. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg. 2000; 66: 827–31.
pubmed: 10993609
Schneider PM, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008; 248: 902–8.
pubmed: 19092334
doi: 10.1097/SLA.0b013e31818f3afb
Brücher BL, Stein HJ, Werner M, Siewert JR. Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer. 2001; 92: 2228–33.
pubmed: 11596042
doi: 10.1002/1097-0142(20011015)92:8<2228::AID-CNCR1567>3.0.CO;2-4
Zhu CM, Ling YH, Xi SY, et al. Prognostic significance of the pN classification supplemented by vascular invasion for esophageal squamous cell carcinoma. PLoS One. 2014; 9: e96129.
pubmed: 24763284
pmcid: 3999115
doi: 10.1371/journal.pone.0096129
Jeon JH, Lee JM, Moon DH, et al. Prognostic significance of venous invasion and maximum standardized uptake value of 18F-FDG PET/CT in surgically resected T1N0 esophageal squamous cell carcinoma. Eur J Surg Oncol. 2017; 43: 471–7.
pubmed: 27912930
doi: 10.1016/j.ejso.2016.11.002
O JH, Jacene H, Luber B, Wang H, et al. Quantitation of cancer treatment response by
pubmed: 28360211
pmcid: 5577628
doi: 10.2967/jnumed.117.189605